<DOC>
	<DOC>NCT02430714</DOC>
	<brief_summary>This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.</brief_summary>
	<brief_title>Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1. All participants with unresectable thyroid cancer and administrated Lenvatinib.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Thyroid Cancer</keyword>
	<keyword>Lenvima</keyword>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>LEN01T</keyword>
	<keyword>All-Patient Investigation</keyword>
	<keyword>Lenvatinib Mesylate</keyword>
</DOC>